Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Orphanet Journal of Rare Diseases, 2021 Background Pleuroparenchymal fibroelastosis (PPFE) has a variable disease course with dismal prognosis in the majority of patients with no validated drug therapy.
Mouhamad Nasser +9 more
doaj +2 more sources
Efficacy of Nintedanib for Idiopathic Pulmonary Fibrosis and Its Safety for Breastfeeding and Pregnancy [PDF]
Scripta Score Scientific Medical JournalBackground : An interstitial lung disease called pulmonary fibrosis can cause breathing difficulties by leaving scars in the lungs. IPF is the most prevalent kind of PF.
Resyana Santoso +2 more
doaj +3 more sources
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
ERJ Open ResearchBackground Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK trial.
R. Gisli Jenkins +9 more
doaj +2 more sources
Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON [PDF]
RMD OpenObjective We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial.Methods Adverse events and changes in FVC over 148 weeks of ...
Yannick Allanore +9 more
doaj +2 more sources
Preparation and characterization of nintedanib nano-liposomes
陆军军医大学学报Objective To investigate the key physical and chemical properties of nintedanib liposomes prepared by 4 different methods in order to screen out the best preparation method of nintedanib liposomes.
RAO Le, GUO Mengyu, XU Guogang
doaj +2 more sources
Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis [PDF]
, 2016 Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis(IPF) and has been shown to slow disease progression by reducing annual lung function decline.
Hagmeyer, Lars +9 more
core +2 more sources
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis [PDF]
, 2014 Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute ...
ÖNGEN, Hürremgül
core +4 more sources
, 2022 αVβ6 Integrin plays a fundamental role in the activation of transforming growth factor-β (TGF-β), the major profibrotic mediator; for this reason, αVβ6 ligands have recently been forwarded to clinical phases for the therapy of fibrotic diseases.
Noemi Monaco (12558516) +9 more
core +1 more source
Treatment with Both Nintedanib and Steroid in Bleomycin-induced Pulmonary Fibrosis Model Mice didn’t Inhibit Lung Fibrosis [PDF]
, 2021 Background：In the clinical setting, the optimal timing of administration of nintedanib in the active or inactive phase of idiopathic pulmonary fibrosis （IPF） has not been clarified.
Sato, Kozo +5 more
core
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases [PDF]
, 2022 Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision ...
José Luis Poveda-Andrés +24 more
core +1 more source